In recent years, particularly following the COVID-19 pandemic, there has been increasing interest in non-invasive respiratory support (RS) to manage the acute hypoxemic respiratory failure (AHRF) [1–3]. This trend has extended beyond intensive care units (ICUs) to a variety of clinical settings, with high-flow nasal oxygen (HFNO) emerging as a promising option for respiratory support [4–6].